Tividenofusp alfa
- Generic Name
- Tividenofusp alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2641020-57-5
- Unique Ingredient Identifier
- QLD7UJN8CF
- Background
Tividenofusp alfa, also known as DNL-310, is a brain-penetrant enzyme replacement therapy being investigated for the treatment of Hunter syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
Denali Therapeutics Reports First Quarter 2024 Financial
Denali Therapeutics reported Q1 2024 financials, highlighting progress in neurodegenerative and lysosomal storage disease treatments. Key updates include positive clinical data for tividenofusp alfa in MPS II, DNL343's Phase 2/3 ALS trial enrollment completion, and advancements in Parkinson’s and Alzheimer’s therapies. The company raised $500M in financing, focusing on BBB-crossing therapeutics.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath